That wait time might be shortened for patients with soft-tissue sarcomas thanks to new research, from the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles (UCLA), demonstrating that PET/CT can be used as early as one week after a single treatment cycle to determine whether the drugs are killing the cancer. Researchers made another surprising discovery—some tumors…
Cancer imaging is one of the most promising medical fields. Hybrid technologies, such as PET/CT or future MRI/PET, are the tools radiologists and oncologists use to gain ever deeper insights into the biological characteristics of tumours. During the Medica Congress the Integrated diagnostics and therapy in oncology imaging session (Thursday 19 November) innovative tools and related developments…
For many indications, because PET-CT produces a very high accuracy for many tumours, this modality is the gold standard, Prof. Reiser confirmed. It also enables good observation of the course of the disease. After an injection of radioactive tracers we can visualise increased metabolic activity in great detail and with high sensitivity. This is an increasingly important issue not only in primary…
If you need to expand your diagnostic imaging services and a fixed installation is too costly but a mobile solution cannot cover your demand, Alliance Medical, Europe's largest provider of out-sourced diagnostic imaging services, reports that it could become your partner. "Did you ever think about a semi-static installation?" the company asks. "The services we can offer by far exceed the…
Alliance Medical is Europe´s largest provider of outsourced diagnostic imaging services, with over 15 years of unparalleled operational and service excellence, with offices in the UK, Ireland, Italy, Spain, Poland, Germany and the Netherlands.
There's no reason to forgo a needed radiation-based medical procedure because of concerns about cancer risk, according to the October issue of Mayo Clinic Health Letter. While the volume of radiation-based tests and procedures has increased in the past three decades, scientists haven't proven that the low doses of radiation used in medical settings actually increase cancer risk.
'Personalized medicine' -- where therapy is designed for the individual patient -- is a popular concept in healthcare today, but according to a new market research report, it will be driven by the imaging industry, especially the new molecular technologies. If images can reveal not just the heightened metabolic activity characteristic of tumors but the tumors' chemical signatures, physicians can…
Chirurgen an der Charité haben in kolorektalem Tumorgewebe eine spezifische Anhäufung von Protoporphyrin-IX (PpIX), einem rot-fluoreszierenden Vorläufermolekül des Häms beobachtet. Wir konnten zeigen, dass diese Anhäufung von PpIX darauf zurückzuführen ist, dass das Enzym, das PpIX normalerweise in Häm überführt, die sogenannte…
Siemens Healthcare reported at the annual meeting of the European Association of Nuclear medicine (EANM) in Barcelona, Spain, that leading hospitals in England, France, Germany and Monaco have shown strong interest and adoption of the Biograph mCT, the worlds first molecular CT, to fuel advanced diagnostic capabilities and to drive greater workflow efficiencies.
Emphasising the crucial partnership of radiologists and urologists in the treatment of prostate cancer, Professor Arnulf Stenzl, Medical Director of Urology at the Tübingen University Hospital, explained that, throughout the phases of prostate cancer diagnosis and therapy - from primary diagnosis onward - imaging is indispensable.
Founded and managed by Prof Peter Schlag, the Charité Comprehensive Cancer Centre (CCCC) co-ordinates cancer diagnostics and therapies across all medical disciplines. Interdisciplinary tumour boards decide on therapies/strategies; cooperation is close with general practitioners, regional hospitals and clinics.
Since its foundation by Michael Friebe PhD in 2003, and on the basis of 10 years of business activity in radiology, Tomovation has become an established provider of high-end services for tomography applications, such as MRI, CT, and PET-CT.
Bayer Schering Pharma AG, Germany, has presented positive data on a global Phase II study with the novel positron emission tomography (PET) tracer florbetaben (BAY 94-9172) at the International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria. This study showed that patients with a clinical diagnosis of Alzheimer´s disease could be differentiated from age-matched healthy volunteers…
Bayer Schering Pharma AG, Germany, has presented positive data on a global Phase II study with the novel positron emission tomography (PET) tracer florbetaben (BAY94-9172) at the International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria. This study showed that patients with a clinical diagnosis of Alzheimer´s disease could be differentiated from age-matched healthy volunteers…
"Radiologists often see cancer patients over a period of years and continuously deliver important information for the treatment process," says Claus D. Claussen MD, Professor of Radiology and Director of the Clinic for Diagnostic and Interventional Radiology at the University Hospital in Tübingen and President of the 90th German Radiology Congress. For the first time in the history of this…
Doctors who frequently recommend inappropriate medical imaging may be financially penalised.
Depending on the institution, CT examination doses can vary dramatically by a factor of ten, said Professor John Damilakis, PhD, associate professor at the University of Crete, Iraklion, ahead of the session. The difference is related principally to variations in the examination technique, as the protocol or the imaging system itself determines the level of radiation.
GE Healthcare's first Discovery PET/CT 600-series scanners are being installed in a number of leading clinics around the world. "This first set of installations is a big step forward in the diagnosis and monitoring of disease", said Terri Bresenham, newly appointed vice- president and general manager of GE Healthcare's global Molecular Imaging business.
Big discussions are expected at the upcoming European Association of Urology (EAU) Congress in Stockholm* when urologist Dr Jochen Walz (right), of the Urological Department at the Institute Paoli-Calmettes, Marseilles, France, presents the forum: Imaging in Europe: Who, where, what, how many! and M F Coelho, of the European Society of Urological Imaging (ESUI) describes the Clinical utility of…
At Medica 2008, Siemens introduced its latest generation PET-CT, the Biograph mCT. During a European Hospital interview, Markus Lusser (ML), worldwide Head of Distribution and Marketing for Molecular Imaging at Siemens, outlined the advantages of the new hybrid system, which aims to extend the spectrum of medical imaging to 'molecular computed tomography'
GE Healthcare showcases its intelligence in PET/CT technology by introducing the latest addition to its PET/CT family, the Discovery PET/CT 600 at the 94th annual Radiological Society of North America annual in Chicago.
Professor Stefan Schönberg of the Institute of Clinical Radiology and Nuclear Medicine (IKRN), University Hospital Mannheim, Medical Faculty of Mannheim, University of Heidelberg, invited colleagues from Mannheim and the Federal Office for Radiation Protection (BFS) in Neuherberg for a round-table discussion on: Non-invasive multidetector coronary CT angiography (CTA) has become an established…
A team of researchers from Brazil recently published details of a free-to-air software called CALDose_X which is being billed as a milestone towards the goal of patient-specific dosimetry in X-ray diagnosis.
The shortage of radiopharmaceuticals due to the planned shutdown of some nuclear reactors will now be discussed by the European Medicines Agency (EMEA). The European Commission (DG Enterprise and Industry) asked EMEA to analyse the extend and to develop potential approaches to address any problems.
The University of Urbino and Philips Research will jointly research the encapsulation of magnetic nanoparticle contrast agents inside living blood cells to prolong the retention time of these agents in the blood. Injected as free particles, magnetic nanoparticle contrast agents are quickly excreted from the blood via the patient's liver, which limits their application.